Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

June 26, 2012

Advances in Inflammation Models and Associated Drug Evaluation: Improved Assessment Using Imaging Biomarkers

Speakers for this Event:
  • James Mobley, Ph.D., Founder and CSO, Sunapten Therapeutics, Inc.  Learn More
  • Patrick McConville, Ph.D., COO, CSO and Co-founder, Molecular Imaging Inc.  Learn More
  • Advances in the understanding of the pathophysiology of human inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease have been aided by the development of clinically translatable animal models, and increasingly sophisticated means of assessing drug efficacy in those models.

    The first generation of rodent arthritis models were highly dependent on the innate immune response to promote joint pain and swelling that was assessed by caliper measurement of the feet and ankles. Corticosteroids and NSAIDs were found to be active in these models.

    The introduction of collagen-induced arthritis and its widespread acceptance in the 1990s added the adaptive immune response to the testable model, and led to the development of clinically successful drugs targeting TNF-a, the IL-6 receptor, B cells, and T cells. The dramatic success of TNF-a antagonists was associated not only with a reduction in pain and swelling, but also a demonstrable impact on reducing bone destruction.

    In the post-TNF era, new drugs hoping to replace TNF antagonists will be required to demonstrate similar if not superior effects on both inflammation and bone destruction. Caliper measurements of ankle swelling are no longer an adequate preclinical endpoint. New technologies such as in vivo multi-modality imaging are providing opportunities to enhance data specificity and predictive power in preclinical and clinical drug testing.

    • This webinar will review models available for assessing anti-inflammatory activity in vivo then focus on imaging technologies, for discovery screening and for translatable biomarkers as applied in inflammation models.
    • Critical advantages to the drug discovery and development process as a result of their implementation will be highlighted.
    • Case studies in two traditional models of rheumatoid arthritis will be used to demonstrate improvement of efficacy assessment and correlation with histopathology through FDG PET and fluorescence imaging based biomarkers, compared with traditional in vivo measurements.

    Senior executives and senior scientists involved in the research & development of anti-inflammatory drugs, including those in the following functional areas:

    • Pre-clinical development
    • Pre-clinical pharmaclology
    • Pre-clinical research
    • Pre-clinical drug development
    • Discovery scientists

    This presentation will also be of interest to those involved in biomarker discovery & development.


    James Mobley, Ph.D., Founder and CSO, Sunapten Therapeutics, Inc

    Dr. Mobley received his PhD in Immunoplogy from the University of Iowa in 1991. Throughout his career Dr. Mobley's research focus has been on models of arthritis and the discovery of novel antiinflammatory agents. He received postdoctoral training at the NIH, the University of Michigan, and in the Cell Biology and Inflammation Research Unit at Pharmacia/UpJohn. He joined the Inflammation Pharmacology Department at Pfizer Global Research and Development in 1997 where he chaired the Inflammation New Targets and Arthritis Disease Area Focus Teams and led a number of Discovery Project Teams focused on Arthritis. Dr. Mobley moved on to become Director of Biology at Lycera Corp. and then founded Sunapten Therapeutics where he serves as CSO. He also serves as Immunoassay R&D Manager at Cayman Chemical.

    Patrick McConville, Ph.D., COO, CSO and Co-founder, Molecular Imaging Inc

    Dr. McConville has over ten years of experience in multi-modality, small-animal imaging with a drug discovery focus, and has specialized in a broad range of disease areas. Dr. McConville is the author of over 20 peer-reviewed publications and book chapters. He received his Ph.D. in Medical Physics from Queensland University of Technology and a B.S. in Physics and Computer Science from the University of South Wales. After postdoctoral work at the NIH, focusing on MR-based assessment of β-adrenergic receptor modulation of cardiac bioenergetics. In 2003, he co founded the first multi-modality preclinical imaging CRO, now known as Molecular Imaging Inc. He established the core multi-modality imaging center and directed implementation, optimization and validation of in vivo imaging protocols across imaging modalities in oncology and inflammatory diseases.


    Molecular Imaging is the only Contract Research Organization (CRO) dedicated to collaborate closely with our clients to answer their small animal in-vivo multi-modality imaging needs (anatomical, functional, molecular). The combination and depth of experience in our pharmacology and imaging teams is what makes us different and a valued partner to the pharmaceutical industry.

    Imaging modalities currently include small animal MRI, PET , CT, bioluminescence, fluorescence, FMT, DEXA, 2D X-ray and in the near future we will be adding many exciting new modalities. Molecular Imaging offers pharmacology models primarily in support of Oncology and Inflammation research. We are also rapidly expanding the number of models available across a range of therapeutic areas through our own R&D program and in collaboration with our clients.

    With nearly a decade of CRO imaging experience, Molecular Imaging combines broad protocol and model validation, optimized image acquisition and analysis throughput, with strong client-oriented project management.

    For information about the recorded archive for this event contact Xtalks at (416) 977-6555 ext 371, or email register@xtalks.com

    Copyright © 2016-2017 Honeycomb Worldwide Inc.